Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Pioneer Drug Designation in Japan for Stargardt diseaseLast subject visit completed in the pivotal Phase 3 DRAGON trial of Tinlarebant in Stargardt diseaseTopline data expected in Q4 2025 SAN DIEGO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug develo

ProPhase Labs Stockholders Deliver Strong Mandate at Special Meeting UNIONDALE, NY, Sept. 12, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics and consumer products company, today announced that stockholders delivered a strong mandate at the Company’s September 9, 2025 Special Meeting, approving all proposals on the agenda. With each proposal receiving more than 75% support, ProPhase received clear authorization to

BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation and clinical progress with the Company’s lead pan-viral protease inhibitor CDI-988 during a podium presentation at the 9th International Calicivirus Conference, held September 7–11, 2025 in Banff, Alberta. Based on a novel mechanism of action and superior broad-spectrum antiviral activity, CDI-988 represents a potential fi

MELBOURNE, Australia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company,” NASDAQ: GELS), a clinical and science-based developer of gel-based oral delivery solutions, welcomes the recently announced product launches of Healthy Extracts, Inc. (“Healthy Extracts,” OTCQB: HYEX), whose products apply Gelteq’s proprietary gel technology, into the U.S. nutraceutical market. The Healthy Extracts products are the first to reach Gelteq’s U.S. warehousing facility using Gelte

Ra’anana, Israel, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary Capture & Contain (C&C) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated targeted deposition in the nasal vestibule—the key ana

GAL-101 was well tolerated; excellent safety and pharmacokinetic profile strongly support oral administrationGAL-101 effectively crosses the blood-brain barrier, supporting further development in Alzheimer’s diseaseA Phase 2 trial in Alzheimer’s disease is planned as the next step, fundraising has been initiated KENSINGTON, Md. and MUNICH and MARTINSRIED, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company deve

NEW YORK, Sept. 12, 2025 /PRNewswire/ -- Blood cancers and disorders affect millions of people across the globe, presenting not only medical challenges but also emotional and financial ones. From leukemia and lymphoma to sickle cell disease and bone marrow disorders, these conditions impact patients and families at every stage of life. To raise awareness during Blood Cancer Awareness Month and beyond, amplify patient voices, and share the latest in diagnostics, therapies, and care, Mediaplanet i

Kuala Lumpur: based private equity firm Creador is set to acquire about 7 per cent stake in domestic pharmaceutical company La Renon Healthcare for ₹800 crore, according to people aware of the development. The transaction values Ahmedabad-headquartered La Renon at nearly ₹11,000 crore and will see a partial stake dilution by the promoter family as well as an existing investor. Promoter Pankaj Singh and family will sell around 5 per cent, while Peak XV Partners (formerly Sequoia Capital) will off

KANAZAWA, Japan, Sept. 12, 2025 /PRNewswire/ -- Researchers at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University , report in ACS Nano , how proteins in cells can be controllably activated through heating, an effect that can be used to initiate programmed cell death. Cellular processes are governed by the activity of proteins. Being able to control the functioning of proteins is therefore highly relevant for the development of biotechnological tools. Doing so with high-enoug

ProRelix Research expands Multi-Country Clinical Trial operations across Europe, Southeast Asia & Thailand, ensuring patient-focused, compliant global studies. Our work is global because patient needs are global. A cancer patient in Boston, Bangalore, or Bangkok is looking for access to new treatments.” — Dr. Sornaraja Thasma, Director - Business & Quality Assurance, ProRelix BOSTON, MA, UNITED STATES, September 12, 2025 / EINPresswire.com / -- ProRelix Research, a leading Contract Research Orga